Adaptive Biotechnologies Corporation (ADPT)
Largest Insider Buys in Sector
ADPT Stock Price History Chart
ADPT Stock Performance
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Insider Activity of Adaptive Biotechnologies Corporation
Over the last 12 months, insiders at Adaptive Biotechnologies Corporation have bought $0 and sold $746,782 worth of Adaptive Biotechnologies Corporation stock.
On average, over the past 5 years, insiders at Adaptive Biotechnologies Corporation have bought $0 and sold $109.87M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 250,000 shares for transaction amount of $5M was made by VIKING GLOBAL PERFORMANCE LLC (10 percent owner) on 2019‑07‑01.
List of Insider Buy and Sell Transactions, Adaptive Biotechnologies Corporation
| 2024-11-18 | Sale | Chief Financial Officer | 248 0.0001% | $4.98 | $1,235 | +34.51% | ||
| 2024-08-22 | Sale | SVP and General Counsel | 26,922 0.0138% | $4.50 | $121,079 | +15.00% | ||
| 2024-03-05 | Sale | CEO and Chairman | 48,673 0.0191% | $3.43 | $167,007 | +14.55% | ||
| 2024-03-05 | Sale | Chief Financial Officer | 15,456 0.0061% | $3.44 | $53,169 | +14.55% | ||
| 2024-03-05 | Sale | President | 39,070 0.0155% | $3.47 | $135,764 | +14.55% | ||
| 2024-03-05 | Sale | Chief Commercial Ofc Imm Med | 29,390 0.0115% | $3.44 | $100,994 | +14.55% | ||
| 2024-03-05 | Sale | Chief People Officer | 14,700 0.0058% | $3.43 | $50,439 | +14.55% | ||
| 2024-03-05 | Sale | Chief Commercial Officer, MRD | 12,991 0.0051% | $3.44 | $44,629 | +14.55% | ||
| 2024-03-05 | Sale | SVP and General Counsel | 13,381 0.0052% | $3.43 | $45,963 | +14.55% | ||
| 2024-03-05 | Sale | Principal Accounting Officer | 7,727 0.003% | $3.43 | $26,504 | +14.55% | ||
| 2023-11-16 | Sale | Principal Accounting Officer | 259 0.0001% | $4.13 | $1,070 | +3.47% | ||
| 2023-08-08 | Sale | Chief Commercial Officer, MRD | 10,550 0.0079% | $6.54 | $68,997 | -37.74% | ||
| 2023-08-07 | Sale | Chief Commercial Officer, MRD | 5,652 0.0044% | $6.78 | $38,321 | -38.21% | ||
| 2023-06-20 | Sale | Chief Financial Officer | 134,961 0.1253% | $8.14 | $1.1M | -47.52% | ||
| 2023-06-15 | Sale | Chief Financial Officer | 14,328 0.0139% | $8.53 | $122,218 | -49.60% | ||
| 2023-06-02 | Sale | Chief Financial Officer | 38,000 0.031% | $7.16 | $272,080 | -40.48% | ||
| 2023-04-11 | Sale | Chief Operating Officer | 2,308 0.0023% | $8.63 | $19,918 | -38.31% | ||
| 2023-04-10 | Sale | Chief Operating Officer | 817 0.0008% | $8.50 | $6,945 | -41.15% | ||
| 2023-03-27 | Sale | director | 2,341 0.0023% | $8.49 | $19,878 | -39.51% | ||
| 2023-03-07 | Sale | Chief Commercial Officer, MRD | 9,813 0.0096% | $8.60 | $84,392 | -28.31% |
Insider Historical Profitability
| ROBINS CHAD M | CEO and Chairman | 2576701 1.746% | $6.76 | 0 | 63 | |
| PETERSON TYCHO | Chief Financial Officer | 531553 0.3602% | $6.76 | 0 | 4 | |
| RUBINSTEIN JULIE | President | 472754 0.3203% | $6.76 | 0 | 62 | |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | 327415 0.2219% | $6.76 | 0 | 2 | |
| LO FRANCIS | Chief People Officer | 253745 0.1719% | $6.76 | 0 | 17 | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | 248290 0.1682% | $6.76 | 0 | 3 | |
| PISKEL KYLE | Chief Financial Officer | 154330 0.1046% | $6.76 | 0 | 5 | |
| Taylor Stacy L | SVP and General Counsel | 139365 0.0944% | $6.76 | 0 | 25 | |
| SPH Group Holdings LLC | 10 percent owner | 41031674 27.8032% | $6.76 | 25 | 0 | |
| STEEL PARTNERS II LP | 10 percent owner | 37094472 25.1353% | $6.76 | 161 | 0 | |
| VIKING GLOBAL PERFORMANCE LLC | 10 percent owner | 30993708 21.0014% | $6.76 | 1 | 2 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 29993708 20.3238% | $6.76 | 0 | 1 | |
| GOEL DAVID E. | See Remarks | 12309090 8.3407% | $6.76 | 0 | 4 | |
| ZOLTNERS ANDRIS A | director | 3621016 2.4536% | $6.76 | 0 | 1 | |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 1594352 1.0803% | $6.76 | 0 | 1 | |
| Sterling Capital Partners III, LLC | 1009813 0.6843% | $6.76 | 0 | 4 | ||
| Sundaresh Subramanian | President & CEO | 333518 0.226% | $6.76 | 1 | 0 | |
| SOOD NITIN | Chief Commercial Officer, MRD | 214808 0.1456% | $6.76 | 0 | 5 | |
| ADAMS R MARK | Chief Operating Officer | 175361 0.1188% | $6.76 | 0 | 8 | |
| Goyal Manoj | VP, Global Product Development | 109000 0.0739% | $6.76 | 0 | 1 | |
| OMEARA CHRISTOPHER G | VP Corp, Fin/CFO | 100000 0.0678% | $6.76 | 0 | 1 | |
| Westfield John M | VP, Corp. Controller | 30721 0.0208% | $6.76 | 0 | 4 | |
| GRIFFIN MICHELLE RENEE | director | 20627 0.014% | $6.76 | 0 | 14 | |
| Noellert John | VP, World Wide Sales | 16666 0.0113% | $6.76 | 0 | 2 | |
| Lowe Marcus D | VP, Marketing & Business Dev. | 13333 0.009% | $6.76 | 0 | 4 | |
| Palaniappan Jyoti | SVP, Diagnostics, T-Detect | 9158 0.0062% | $6.76 | 0 | 6 | |
| Pellini Michael J | director | 1504 0.001% | $6.76 | 0 | 3 | |
| DOBMEIER ERIC | director | 0 0% | $6.76 | 0 | 8 | |
| Dotz Mary | Chief Financial Officer | 0 0% | $6.76 | 1 | 2 | |
| SANG CHARLES | SVP, External Affairs | 0 0% | $6.76 | 0 | 4 |